9.19

1.32% 0.12

Amicus Therapeutics Inc (FOLD)

Overview News Price History Option Chain Financials Why FOLD Down? Discussions Forecast

Amicus Therapeutics Inc stock is traded at $9.19, with a volume of 2.57M. It is up +1.32% in the last 24 hours and down -3.36% over the past month. Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Previous Close:

$9.07

Open:

$9.15

24h Volume:

2.57M

Relative Volume:

1.14

Market Cap:

$2.76B

Revenue:

$493.67M

Net Income/Loss:

$-104.69M

P/E Ratio:

-27.03

EPS:

-0.34

Net Cash Flow:

$-31.51M

1W Performance:

-5.94%

1M Performance:

-3.36%

6M Performance:

-23.99%

1Y Performance:

-32.23%

1-Day Range:

$9.02

$9.26

1-Week Range:

$9.02

$10.00

52-Week Range:

$8.785

$14.02

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name

Amicus Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

(609) 662-2000

Address

47 HULFISH STREET, PRINCETON, NJ

Employee

499

Twitter

@amicusrx1

Next Earnings Date

2024-11-06

Latest SEC Filings

FOLD's Discussions on Twitter

Compare FOLD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FOLD Amicus Therapeutics Inc	9.19	2.76B	493.67M	-104.69M	-31.51M	-0.34
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-06-24	Initiated	Jefferies	Buy
May-30-24	Initiated	Wells Fargo	Overweight
May-14-24	Upgrade	Guggenheim	Neutral → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Apr-13-22	Resumed	Goldman	Neutral
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-15-21	Upgrade	Stifel	Hold → Buy
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight
Jul-19-21	Resumed	BTIG Research	Buy
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-02-21	Initiated	Stifel	Hold
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight
Dec-10-20	Downgrade	Citigroup	Buy → Neutral
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy
Feb-04-20	Resumed	Cantor Fitzgerald	Overweight
Nov-12-19	Reiterated	H.C. Wainwright	Buy
Jun-17-19	Initiated	H.C. Wainwright	Buy
Jun-05-19	Reiterated	Cantor Fitzgerald	Overweight
Apr-05-19	Initiated	Janney	Buy
Jan-30-19	Initiated	Cantor Fitzgerald	Overweight
Oct-29-18	Initiated	Citigroup	Neutral
Aug-17-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-06-17	Resumed	Goldman	Neutral
Sep-13-17	Reiterated	Chardan Capital Markets	Buy
Aug-10-17	Reiterated	Chardan Capital Markets	Buy
Jan-24-17	Upgrade	Robert W. Baird	Neutral → Outperform
May-18-16	Initiated	BofA/Merrill	Buy
Apr-14-16	Initiated	Robert W. Baird	Neutral
Apr-12-16	Reiterated	Chardan Capital Markets	Buy
Sep-16-15	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-16-15	Reiterated	Chardan Capital Markets	Buy

View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

07:29 AM

Transcend Capital Advisors LLC Acquires 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

07:29 AM

Feb 21, 2025

Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia

Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN

Feb 21, 2025

Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India

Feb 21, 2025

Amicus Therapeutics files prospectus for stock sales - Investing.com India

Feb 21, 2025

Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com

Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat

Feb 21, 2025

Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.

Feb 21, 2025

Wells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat

Feb 21, 2025

Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat

Feb 21, 2025

Amicus Therapeutics (FOLD) Expected to Announce Earnings on Wednesday - MarketBeat

Feb 21, 2025

Feb 20, 2025

Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN

Feb 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat

Feb 20, 2025

Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat

Feb 20, 2025

Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN

Feb 20, 2025

Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Feb 20, 2025

Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net

Feb 20, 2025

Feb 19, 2025